» Articles » PMID: 19632080

Influence of Neoadjuvant Radio-chemotherapy on Tumor-infiltrating Lymphocytes in Squamous Esophageal Cancer

Overview
Publisher Elsevier
Date 2009 Jul 28
PMID 19632080
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Data on influence of radio-chemotherapy (RCT) on tumor-infiltrating lymphocytes (TILs) is scarce and no study addressed this issue in esophageal squamous cell cancer (SCC) so far.

Methods: Tumor specimens of 49 patients with SCC were re-evaluated with immunohistochemical staining with anti-CD3, anti-CD4, anti-CD8, anti-CD25 and anti-FOXP3 antibodies. Lymphocytes were counted in one high power field (0.189 mm(2)) at the periphery and in the centre of tumors.

Results: 21 patients received preoperative RCT, 28 proceeded directly to surgery. There was no significant difference in survival between the two groups (median survival 23.2 months vs. 22.1 months, log rank test p=n.s.). Cox regression analysis showed that no variable had a significant effect on survival. The infiltrating pattern of TILs revealed higher numbers peripherally independent of the administration of RCT. There was a significant decrease in all cell numbers except CD4(+) cells in the centre of the tumors after RCT (CD3(+)p=0.005; CD8(+)p=0.02; CD25(+)p=0.01; FoxP3(+)p=0.01). There were fewer TILs in the periphery after RCT; however, this difference only reached significance in FoxP3(+) cells (p=0.01).

Conclusion: Neoadjuvant RCT reduced the number of TILs in esophageal SCC. This was primarily seen in the centre of tumors and suggests that the effect of RCT on immunological response is located in the centre of tumors.

Citing Articles

Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.

Habu T, Kumagai S, Bando H, Fujisawa T, Mishima S, Kotani D J Gastroenterol. 2024; 59(9):798-811.

PMID: 38819498 DOI: 10.1007/s00535-024-02120-z.


Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.

Farinha H, Digklia A, Schizas D, Demartines N, Schafer M, Mantziari S Cancers (Basel). 2022; 14(3).

PMID: 35158822 PMC: 8833794. DOI: 10.3390/cancers14030554.


Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.

Soeratram T, Creemers A, Meijer S, de Boer O, Vos W, Hooijer G J Pathol. 2021; 256(3):282-296.

PMID: 34743329 PMC: 9299918. DOI: 10.1002/path.5832.


Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?.

Vivaldi C, Catanese S, Massa V, Pecora I, Salani F, Santi S Int J Mol Sci. 2020; 21(5).

PMID: 32121290 PMC: 7084692. DOI: 10.3390/ijms21051658.


SIX1 overexpression predicts poor prognosis and induces radioresistance through AKT signaling in esophageal squamous cell carcinoma.

He Z, Li G, Tang L, Li Y Onco Targets Ther. 2017; 10:1071-1079.

PMID: 28260921 PMC: 5328293. DOI: 10.2147/OTT.S125330.